ClinicalTrials.gg
CompletedNCT03405389MatrixWAVEUpdated Sep 16, 2025

Focused Registry to Collect Clinical Data on the MatrixWAVE System

An observational study in Mandibular Fractures, sponsored by AO Innovation Translation Center. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by AO Innovation Translation Center · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
44
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 14 studies in Mandibular Fractures with a site in United States — 1 open to participants now, 3 under way, none of them phase 3. Mandibular Fractures · United States.

Started
2019
with 1 other
Observational
8 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
1 of 14
AO Innovation Translation Center

Among the 14 studies in Mandibular Fractures with a site in United States, this one is one of 2 that started in 2019, is one of 8 observational ones, and was the 5th registered.

By phase

14 studies; the count open now beside each. This study's row is marked.

Observationalthis study8 · 1 open
No phase6 · 0 open

By the year they started

First in 2013; this study’s year is marked. 2 started in 2019.

What they test

Size and results

Median enrollment 48 across the 6 interventional studies, 47 across the 8 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 14 studies in Mandibular Fractures with a site in United States, or all of them as a file.
02

Study summary

The goal of this registry is to evaluate the performance of the MatrixWAVE(TM) MMF system in patients suffering from non-condylar and/or condylar fractures. The evaluation will focus on the clinical performance in terms of :

  • surgical technique
  • application time
  • intra- and postoperative complications
  • short term patient-reported outcomes
Read the detailed description

Following standard of care (routine) procedures, a total number of 50 patients suffering from non-condylar and/or condylar fractures of the mandible requiring MMF for a minimum of two weeks during or subsequent to open reduction internal fixation (ORIF) will be prospectively enrolled in this registry.

Data on the classification of the injury (AO CMF fracture classification system) and the time needed for application of the MatrixWAVE(TM) MMF system will be collected.

Follow-up (FU) visits will be performed between 2 to 6 weeks and at 3 months according to standard of care to evaluate the mandible function impairment, pain and local complications (anticipated procedure-related adverse events) related to the MatrixWAVE(TM) MMF system.

03

Conditions studied

  • Mandibular Fractures

Keywords

  • mandibulo-maxillary fixation
  • malocclusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients older than 18 years old suffering with a mandibilar fracture without involvement of the condyle(s) or maxilla.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older at the time of the surgery
  • Diagnosis of a mandibular fracture requiring ORIF and use of MMF during or subsequent to surgical intervention for a minimum of two weeks
  • obtained, i.e.:

    • Ability to understand the content of the patient information/ICF
    • Willingness and ability to participate in the clinical investigation according to the Registry Plan (RP)
    • Signed and dated EC/IRB approved written informed consent

Exclusion criteria

Exclusion Criteria:

  • Pre-traumatic non-occlusion due to hypodontia, edentulousness or severe malalignment of dental arches (e.g. complete crossbite)
  • Concomitant maxillary fracture (e.g. Le Fort)
  • Any not medically managed severe systemic disease
  • Recent history of substance abuse (i.e. recreational drugs, alcohol) that would preclude reliable assessment
  • Pregnancy or women planning to conceive within the registry period
  • Prisoner
  • Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present registry
  • Intra-operative decision of the surgeon to use other MMF systems than the MatrixWAVE MMF system
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
44 participants (actual)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Patients

    Patients diagnosis of a mandibular fracture requiring Open Reduction and Internal Fixation (ORIF) and use of Mandibulo-Maxillary fixation (MMF) during or subsequent to surgical intervention for a minimum of two weeks

    Procedure: MatrixWAVE MMF System

Interventions

  • ProcedureMatrixWAVE MMF System

    Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion

06

What researchers measure

Primary outcomes

  1. Time of application

    Time required by the surgeons to apply the MatrixWAVE MMF system

    Time frame: Intraoperative

Secondary outcomes

  1. Patient-reported outcome (Likert scale)

    Effect of MatrixWAVE MMF system on daily-life activities (speaking, eating and chewing, kissing)

    Time frame: 6 weeks

07

Study locations

2 sites
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029-6574, United States
  • Ludwig-Maximillians University
    München, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Apr 2025, 69 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2018
First posted
Jan 23, 2018
StartActual
Jun 20, 2019
Primary completionActual
Apr 1, 2025
CompletionActual
Apr 1, 2025
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03405389
Lead sponsor
AO Innovation Translation Center
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Jun 20, 2019
Primary completion
Apr 1, 2025
Completion
Apr 1, 2025
Last update
Sep 16, 2025

Study contacts

Paris Liokatis, Dr. med.
principal investigator · Klinikum der Universität München

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion